-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Oppenheimer Lowers Nkarta (NASDAQ:NKTX) to Market Perform
Oppenheimer Lowers Nkarta (NASDAQ:NKTX) to Market Perform
Oppenheimer lowered shares of Nkarta (NASDAQ:NKTX – Get Rating) from an outperform rating to a market perform rating in a research note published on Thursday, Marketbeat.com reports.
A number of other research firms have also recently commented on NKTX. Mizuho cut their target price on shares of Nkarta from $81.00 to $26.00 and set a buy rating for the company in a research note on Wednesday, November 16th. Cantor Fitzgerald reissued an overweight rating on shares of Nkarta in a research note on Wednesday, September 21st. Canaccord Genuity Group started coverage on shares of Nkarta in a research note on Monday, October 10th. They set a buy rating and a $25.00 target price for the company. Finally, Canaccord Genuity Group began coverage on shares of Nkarta in a research note on Monday, October 10th. They set a buy rating and a $25.00 target price for the company. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, the company has an average rating of Moderate Buy and a consensus price target of $29.90.
Get Nkarta alerts:Nkarta Stock Performance
NKTX opened at $5.54 on Thursday. The stock has a market capitalization of $270.43 million, a price-to-earnings ratio of -2.07 and a beta of -0.06. The company has a fifty day moving average of $9.73 and a two-hundred day moving average of $12.44. Nkarta has a fifty-two week low of $5.22 and a fifty-two week high of $20.35.
Insider Buying and Selling at Nkarta
In other Nkarta news, CEO Paul J. Hastings sold 23,376 shares of the business's stock in a transaction dated Wednesday, September 28th. The shares were sold at an average price of $13.03, for a total value of $304,589.28. Following the transaction, the chief executive officer now directly owns 250,959 shares in the company, valued at approximately $3,269,995.77. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 5.60% of the stock is currently owned by company insiders.Hedge Funds Weigh In On Nkarta
Several institutional investors and hedge funds have recently bought and sold shares of NKTX. Federated Hermes Inc. boosted its holdings in Nkarta by 735.3% in the 1st quarter. Federated Hermes Inc. now owns 4,711 shares of the company's stock valued at $54,000 after purchasing an additional 4,147 shares during the last quarter. Wasatch Advisors Inc. boosted its holdings in Nkarta by 33.4% in the 1st quarter. Wasatch Advisors Inc. now owns 842,302 shares of the company's stock valued at $9,585,000 after purchasing an additional 210,700 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Nkarta by 69.7% in the 1st quarter. Renaissance Technologies LLC now owns 234,000 shares of the company's stock worth $2,663,000 after acquiring an additional 96,100 shares during the last quarter. State Street Corp lifted its holdings in shares of Nkarta by 1.0% in the 1st quarter. State Street Corp now owns 276,318 shares of the company's stock worth $3,144,000 after acquiring an additional 2,806 shares during the last quarter. Finally, Deep Track Capital LP lifted its holdings in shares of Nkarta by 67.2% in the 1st quarter. Deep Track Capital LP now owns 2,113,795 shares of the company's stock worth $24,055,000 after acquiring an additional 849,369 shares during the last quarter. 87.22% of the stock is currently owned by institutional investors and hedge funds.
About Nkarta
(Get Rating)
Nkarta, Inc, a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells.
See Also
- Get a free copy of the StockNews.com research report on Nkarta (NKTX)
- MarketBeat: Week in Review 12/19 – 12/23
- These Steelmakers Deserve A Place On Your 2023 Watch List
- Inflation Cools, Where Does The S&P 500 Go Now
- Cintas Beats Inflation With Operating Leverage
- Your Decision to Buy Palantir May Simply Be a Matter of Time
Receive News & Ratings for Nkarta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nkarta and related companies with MarketBeat.com's FREE daily email newsletter.
Oppenheimer lowered shares of Nkarta (NASDAQ:NKTX – Get Rating) from an outperform rating to a market perform rating in a research note published on Thursday, Marketbeat.com reports.
据Marketbeat.com报道,在周四发布的一份研究报告中,奥本海默将恩卡塔(纳斯达克代码:NKTX-GET Rating)的股票评级从表现优于大盘下调至市场表现。
A number of other research firms have also recently commented on NKTX. Mizuho cut their target price on shares of Nkarta from $81.00 to $26.00 and set a buy rating for the company in a research note on Wednesday, November 16th. Cantor Fitzgerald reissued an overweight rating on shares of Nkarta in a research note on Wednesday, September 21st. Canaccord Genuity Group started coverage on shares of Nkarta in a research note on Monday, October 10th. They set a buy rating and a $25.00 target price for the company. Finally, Canaccord Genuity Group began coverage on shares of Nkarta in a research note on Monday, October 10th. They set a buy rating and a $25.00 target price for the company. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, the company has an average rating of Moderate Buy and a consensus price target of $29.90.
其他一些研究公司最近也对NKTX发表了评论。瑞穗在11月16日周三的一份研究报告中将Nkarta的股票目标价从81.00美元下调至26.00美元,并为该公司设定了买入评级。康托·菲茨杰拉德在9月21日星期三的一份研究报告中重新发布了对Nkarta股票的增持评级。Canaccel Genuity Group在10月10日星期一的一份研究报告中开始对Nkarta的股票进行报道。他们为该公司设定了买入评级和25.00美元的目标价。最后,Canaccel Genuity Group在10月10日星期一的一份研究报告中开始报道Nkarta的股票。他们为该公司设定了买入评级和25.00美元的目标价。一名投资分析师对该股的评级为持有,9名分析师对该公司的评级为买入。根据MarketBeat的数据,该公司的平均评级为中等买入,共识目标价为29.90美元。
Nkarta Stock Performance
Nkarta股票表现
NKTX opened at $5.54 on Thursday. The stock has a market capitalization of $270.43 million, a price-to-earnings ratio of -2.07 and a beta of -0.06. The company has a fifty day moving average of $9.73 and a two-hundred day moving average of $12.44. Nkarta has a fifty-two week low of $5.22 and a fifty-two week high of $20.35.
NKTX周四开盘报5.54美元。该股市值为2.7043亿美元,市盈率为-2.07倍,贝塔系数为-0.06。该公司的50日移动均线切入位在9.73美元,200日移动均线切入位在12.44美元。Nkarta的52周低点为5.22美元,52周高位为20.35美元。
Insider Buying and Selling at Nkarta
恩卡尔塔的内幕买卖
Hedge Funds Weigh In On Nkarta
对冲基金对Nkarta进行加码
Several institutional investors and hedge funds have recently bought and sold shares of NKTX. Federated Hermes Inc. boosted its holdings in Nkarta by 735.3% in the 1st quarter. Federated Hermes Inc. now owns 4,711 shares of the company's stock valued at $54,000 after purchasing an additional 4,147 shares during the last quarter. Wasatch Advisors Inc. boosted its holdings in Nkarta by 33.4% in the 1st quarter. Wasatch Advisors Inc. now owns 842,302 shares of the company's stock valued at $9,585,000 after purchasing an additional 210,700 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Nkarta by 69.7% in the 1st quarter. Renaissance Technologies LLC now owns 234,000 shares of the company's stock worth $2,663,000 after acquiring an additional 96,100 shares during the last quarter. State Street Corp lifted its holdings in shares of Nkarta by 1.0% in the 1st quarter. State Street Corp now owns 276,318 shares of the company's stock worth $3,144,000 after acquiring an additional 2,806 shares during the last quarter. Finally, Deep Track Capital LP lifted its holdings in shares of Nkarta by 67.2% in the 1st quarter. Deep Track Capital LP now owns 2,113,795 shares of the company's stock worth $24,055,000 after acquiring an additional 849,369 shares during the last quarter. 87.22% of the stock is currently owned by institutional investors and hedge funds.
几家机构投资者和对冲基金最近买卖了NKTX的股票。联合爱马仕公司在第一季度增持了735.3%的恩卡尔塔股份。联合爱马仕公司现在拥有4,711股该公司股票,价值54,000美元,在上个季度又购买了4,147股。Wasatch Advisors Inc.在第一季度将其在Nkarta的持股增加了33.4%。Wasatch Advisors Inc.在上个季度额外购买了210,700股票后,现在拥有842,302股该公司股票,价值9,585,000美元。复兴科技有限责任公司在第一季度增持了69.7%的Nkarta股票。复兴科技有限责任公司在上个季度增持了96,100股后,目前持有该公司23.4万股股票,价值2,663,000美元。道富银行在第一季度增持了1.0%的Nkarta股票。道富银行目前持有276,318股该公司股票,价值3,144,000美元,此前该公司在上个季度又收购了2,806股。最后,Deep Track Capital LP在第一季度增持了67.2%的Nkarta股票。Deep Track Capital LP在上个季度额外收购了849,369股后,现在拥有2,113,795股该公司股票,价值24,055,000美元。87.22%的股票目前由机构投资者和对冲基金持有。
About Nkarta
关于恩卡尔塔
(Get Rating)
(获取评级)
Nkarta, Inc, a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells.
Nkarta,Inc.是一家临床阶段的生物制药公司,开发和商业化癌症治疗的细胞疗法。该公司的细胞免疫疗法涉及自然杀伤(NK)细胞表面的嵌合抗原受体,使细胞能够识别肿瘤细胞表面存在的特定蛋白质或抗原。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Nkarta (NKTX)
- MarketBeat: Week in Review 12/19 – 12/23
- These Steelmakers Deserve A Place On Your 2023 Watch List
- Inflation Cools, Where Does The S&P 500 Go Now
- Cintas Beats Inflation With Operating Leverage
- Your Decision to Buy Palantir May Simply Be a Matter of Time
- 免费获取StockNews.com关于NKTX的研究报告
- MarketBeat:回顾一周12/19-12/23
- 这些钢铁制造商理应在2023年观察名单上占有一席之地
- 通胀降温,标普500指数何去何从
- Cintas以经营杠杆击败通胀
- 你买下Palantir的决定可能只是个时间问题
Receive News & Ratings for Nkarta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nkarta and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Nkarta Daily》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Nkarta和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧